Cilostazol reduces restenosis in infrapopliteal angioplasty

Original title: Impact of Cilostazol on Angiographic Restenosis after Balloon Angioplasty for Infrapopliteal Artery Disease in Patients with Critical Limb Ischemia Reference: Y. Soga et al. European Journal of Vascular and Endovascular Surgery 44 (2012) 577e581.

Angioplasty is regularly used for patients with critical limb ischemia where restenosis is a great limitation, especially in infrapopliteal territory. 

The use of stents and paclitaxel eluting balloons seems promising; however using it in all infrapopliteal lesions is not affordable. The aim of this study that included 63 patients (32 in the cilostazol group and 31 in the control group) was to assess whether cilostazol reduces binary restenosis at three months follow up. All patients presented critical limb ischemia.

Cilostazol group showed lower binary restenosis (56% vs. 86%, p=0,015), lower reocclusion (20,5% vs. 42,1%, p=0,02) and lower target lesion revascularization (27,5% vs 49,1%) compared to the control group. Looking at clinical outcomes of affected limbs, instead of the angiographical lesions, no differences were found between the two groups, as regards both ulcer healing and member salvage.

Conclusion 

Cilostazol could reduce restenosis and revascularization after infrapopliteal angioplasty in patients with critical limb ischemia.

Editorial Comment:

This work has several important limitations such as the fact that it was a retrospective analysis and that cilostazol was indicated following operator’s criterion. The small number of patients enrolled in this study is also a limitation, as well as follow at three months. On the other hand, this study shows real life results (they did not use drug eluting stents or balloons) of infrapopliteal limb salvage angioplasty where all additional measures can have relative impact in the context of such poor results. No one can doubt that, though promising, cilostazol needs further randomized studies assessment.

SOLACI.ORG

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....